Abstract: A compound of the general formula (I), ##STR1## is described wherein R.sup.1 and R.sup.5 each represent a phenyl group optionally substituted with 1 to 3 lower alkoxy, halo, lower alkyl, monohalo-(lower)-alkyl, dihalo-(lower)-alkyl and/or trihalo-(lower)-alkyl groups, R.sup.2 stands for hydrogen or a lower alkyl group optionally substituted with a hydroxy group or 1 to 3 halogen atoms, R.sup.3 and R.sup.4 each represent a hydrogen atom or a lower alkyl group, and R.sup.6 stands for a carbamoyl, thiocarbamoyl or amidino group having optionally one or two lower alkyl and/or lower alkoxycarbonyl substitutes, or a group of the general formula R.sup.7 -CO-wherein R.sup.7 stands for a lower analkoxy group, an aryloxy group, or an aralkoxy group, and n is equal to 0, provided that when R.sup.1 and R.sup.5 each represent a phenyl group, R.sup.2 and R.sup.3 may not stand for hydrogen or a pharmaceutically acceptable acid addition salt, a pure isomer or an isomeric mixture thereof.

Abstract: New steroid-spiro-oxathiazolidine derivatives pharmaceutical compositions containing the same, and to a process for the preparation thereof are disclosed.The new compounds have antimineral corticoide effects and have the following formula (I), ##STR1## wherein R.sub.1 is a C.sub.1-3 alkyl or a C.sub.2-4 alkenyl group, andZ is a group of the formulae (II) to (VI), ##STR2## wherein R.sub.2 is methyl or ethyl,R.sub.3 is hydrogen or methylR.sub.4 is hydrogen, a C.sub.1-3 alkyl group, a di-(C.sub.1-4 alkyl)-amino-C.sub.1-4 alkyl group, a C.sub.2-4 alkylcarbonyl group, a C.sub.2-4 alkoxycarbonyl group or a C.sub.3-6 carboxyalkylcarbonyl group, andthe dotted lines may represent additional valence bonds, with the proviso that if Z is a group of the formula (VI), a double bond exists between the carbon atoms in positions 4 and 5 or 5 and 6, andif R.sub.4 is a di-(C.sub.1-4 alkyl)-amino-C.sub.1-4 alkyl group or a C.sub.3-6 carboxyalkylcarbonyl group, the compounds may also be formed as their salts.

Abstract: Compounds of the formula (I) having aldosterone-antagonizing activity are disclosed ##STR1## wherein R.sub.3 and R.sub.4 are each C.sub.1 to C.sub.3 alkyl; andZ is one of the following groups ##STR2## wherein R.sub.1 is hydrogen or methyl;R.sub.6 is hydrogen, C.sub.1 to C.sub.3 alkylthio or C.sub.2 to C.sub.4 acylthio; andX is oxo, hydroximino, C.sub.1 to C.sub.3 alkoxyimino, carboxy-alkoxyimino wherein the alkoxy has 2 to 4 carbon atoms or a salt-converted carboxy-alkoxy-imino wherein the alkoxy has 2 to 4 carbon atoms.

Abstract: The invention relates to new compounds of the general formula (I), ##STR1## wherein R.sup.1 and R.sup.5 each represent a phenyl group, optionally substituted,R.sup.2 stands for hydrogen, formyl group, carboxy group, lower alkoxycarbonyl group, hydroxy-(lower)-alkoxycarbonyl group, or a lower alkyl group, optionally substituted,R.sup.3 and R.sup.4 each represent hydrogen atom or a lower alkyl group, with the proviso that when R.sup.1 and R.sup.5 each represent a phenyl group, R.sup.2 and R.sup.3 may not stand for hydrogen.These compounds possess valuable biological properties, and can be applied primarily as antiphlogistic or diuretic agents.

Abstract: Diuretic pharmaceutically active steroid-spiro-oxazolidinone compounds of the formula (I), ##STR1## wherein R.sup.1 is hydrogen or methyl,R.sup.2 is C.sub.1-4 alkyl,R.sup.3 is hydrogen, C.sub.1-4 alkyl or C.sub.2-4 alkenyl,Z.sup.1 and Z.sup.2 each are hydrogen or together form a second valence bond, or Z.sup.1 is hydrogen and Z.sup.2 is R.sup.4 --S--,Z.sup.3 and Z.sup.4 each are hydrogen or together form a second valence bond, or Z.sup.3 is hydrogen and Z.sup.4 is R.sup.4 --S--, with at least one of the pairs Z.sup.1 -Z.sup.2 and Z.sup.3 -Z.sup.4 representing hydrogen and an R.sup.4 --S-- group, andR.sup.4 is hydrogen or alkyl, alkenyl, aralkyl or acyl with up to 7 carbon atoms, provided that when Z.sup.1 and Z.sup.2 together form a valence bond, or Z.sup.1 represents a hydrogen atom and Z.sup.2 and R.sup.4 --S-- group then R.sup.1 is methyl.

Abstract: The invention relates to novel spirooxazolidines represented by the formula I ##STR1## wherein R.sub.1 is alkyl having from 1 to 4 carbon atoms;R.sub.2 is hydrogen, alkyl having from 1 to 4 carbon atoms, alkenyl having from 1 to 4 carbon atoms, or dialkylphosphinoxymethyl having in the alkyl moiety from 1 to 3 carbon atoms each;Z is one of the groups represented by the formulae III to XIV as subsequently defined therein.

Abstract: Novel 6-amino-5.alpha.,19-cycloandrostane derivatives of formula I and their pharmaceutically acceptable addition salts ##STR1## wherein X denotes any of the groups of the formula =CH(OR), =CO or =C=N-OR.sub.1,Y denotes any of the groups of the formula =CO, =CH(OR.sub.1), =C=N-OR.sub.1, =C(OR.sub.1)-C.tbd.CH or ##STR2## wherein R denotes a hydrogen atom, a C.sub.1-4 alkyl group or a C.sub.2-5 acyl group, andR.sub.1 denotes a hydrogen atom, a straight-chained or branched C.sub.1-5 alkyl group, a straight-chained or branched C.sub.1-5 hydroxyalkyl group, a C.sub.3-8 cycloalkyl group, an allyl group, or a benzyl group, andR.sub.3 has the same meaning as R.sub.2 but if R.sub.2 is a sec. or tert. alkyl group or an alicyclic group, then R.sub.3 can only be a hydrogen atom; and if R.sub.2 is a benzyl group then R.sub.3 can only be a hydrogen atom or a primary alkyl group, furtherR.sub.2 and R.sub.3 may denote together with the adjcacent nitrogen atom a piperidine, a morpholine, or an N-methylpiperazine group.